Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yasuhisa Fujii
Institution:
Institute of Science Tokyo
Observed institution:
Institute of Science Tokyo
ORCID:
0000-0002-6761-3229
Observed ORCID:
0000-0002-6761-3229
OpenAlex ID:
A5121895962
Time-Dependent Comparative Effectiveness of First-Line Treatment for Metastatic Clear Cell Renal Cell Carcinoma: A Restricted Mean Survival Time-Based Network Meta-analysis
2026
·
Hiroshi Fukushima
, Shugo Yajima
, et al.
·
Targeted Oncology
·
7
Bayesian Methods for Subgroup Efficacy and Safety: Application to Japanese Patients in JAVELIN Renal 101
2026
·
Hiroshi Fukushima
, Soichiro Yoshida
, et al.
·
JCO Clinical Cancer Informatics
·
2
Exploratory Time‐Dependent Patterns in Estimated Treatment Effect of Talazoparib Plus Enzalutamide in HRR Non‐Deficient or Unknown Metastatic Castration‐Resistant Prostate Cancer: A Post Hoc Analysis of the TALAPRO ‐2 Trial
2026
·
Shugo Yajima
, Soichiro Yoshida
, et al.
·
International Journal of Urology
·
1
Real-world insights from comprehensive genomic profiling in patients with metastatic castration-resistant prostate cancer
2026
·
Yosuke Yasuda
, Soichiro Yoshida
, et al.
·
Japanese Journal of Clinical Oncology
·
1
Time-dependent effects of BCG plus immune checkpoint inhibitors in BCG-naive high-risk non-muscle-invasive bladder cancer: a reconstructed patient-level analysis
2026
·
Shugo Yajima
, Soichiro Yoshida
, et al.
·
International Urology and Nephrology
Survival benchmarking of talazoparib plus enzalutamide in homologous recombination repair-deficient metastatic castration-resistant prostate cancer: a reconstructed individual patient data analysis
2026
·
Hiroki Tanaka
, Hiroshi Fukushima
, et al.
·
Japanese Journal of Clinical Oncology
C-reactive protein at pembrolizumab initiation and its trajectory from first-line chemotherapy as prognostic markers in metastatic urothelial carcinoma (YUSHIMA study)
2026
·
Shugo Yajima
, Soichiro Yoshida
, et al.
·
International Urology and Nephrology
A Bayesian reanalysis of the THOR trial cohort 1 using reconstructed individual patient data: interval-specific effects and clinically interpretable estimands under non-proportional hazards
2026
·
Gaku Okumura
, Soichiro Yoshida
, et al.
·
Japanese Journal of Clinical Oncology
Bayesian re-analysis of ERA223 and PEACE-3 temporal dynamics and bone protection in radium-223-treated metastatic castration-resistant prostate cancer
2026
·
Wei Chen
, Soichiro Yoshida
, et al.
·
Japanese Journal of Clinical Oncology
Bayesian reanalysis of the NIAGARA trial using reconstructed individual patient data: perioperative durvalumab in cisplatin-eligible muscle-invasive bladder cancer
2026
·
Kohei Hirose
, Soichiro Yoshida
, et al.
·
Japanese Journal of Clinical Oncology
A probabilistic multicriteria decision analysis of robot-assisted versus laparoscopic sacrocolpopexy: a secondary analysis of published meta-analytic data
2026
·
Shunya Matsumoto
, Soichiro Yoshida
, et al.
·
Journal of Robotic Surgery
Durable Disease Control With Nivolumab in Malignant Epithelioid Angiomyolipoma: A Case Report
2026
·
Hiroki Shimoda
, Shohei Fukuda
, et al.
·
IJU Case Reports
Lymph node metastasis as a favorable prognostic factor in metastatic urothelial carcinoma with histological variants treated with pembrolizumab: a retrospective multicentric study (YUSHIMA study-04)
2026
·
Ichiro Yonese
, Fumitaka Koga
, et al.
·
Japanese Journal of Clinical Oncology
PDF
Androgen Receptor Signaling Inhibitors for Metastatic Hormone Sensitive Prostate Cancer in Asians: Indirect Comparison
2026
·
Wei Chen
, Soichiro Yoshida
, et al.
·
Cancer Reports
PDF
Quantifying benefit of adding docetaxel to androgen receptor-axis therapy in metastatic hormone-sensitive prostate cancer with Bayesian analysis
2026
·
Wei Chen
, Soichiro Yoshida
, et al.
·
International Urology and Nephrology
Show more works
View as search
Works count:
15
Citation count:
11
H-index:
2
I10-index:
Year
Topic
Type